NUVBbenzinga

Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval

Summary

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on June 11, 2025 by benzinga